Literature DB >> 17506848

Port-site and liver metastases after laparoscopic pelvic and para-aortic lymph node dissection for surgical staging of locally advanced cervical cancer.

J-Y Park1, M C Lim, S Y Lim, J-M Bae, C W Yoo, S-S Seo, S Kang, S-Y Park.   

Abstract

Recently, we experienced a case of port-site and liver metastases after 75 cases of laparoscopic transperitoneal pelvic lymph node dissection (PLND) and para-aortic lymph node dissection (PALND) for surgical staging of locally advanced cervical cancer. A 45-year-old-woman with stage IIB cervical adenocarcinoma underwent laparoscopic PLND and PALND for surgical staging. There was no intraperitoneal disease and cervical tumor was not manipulated at the time of laparoscopic surgery. Pathologic examination revealed only one micrometastasis in left internal iliac lymph node (LN), measuring 1 mm, of the 60 pelvic and para-aortic LNs removed. She received concurrent chemoradiation therapy and pelvic mass disappeared completely. One month after the completion of therapy, both lateral and umbilical port-site and liver metastases were detected. We conclude that although cases of port-site metastasis have mostly occurred after extensive disease, the possibility of such complication should be kept in mind at laparoscopy of early cancer and laparoscopy which does not manipulate primary tumor.

Entities:  

Mesh:

Year:  2007        PMID: 17506848     DOI: 10.1111/j.1525-1438.2007.00972.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  9 in total

1.  Twist-related protein 1-mediated regulation of mesenchymal change contributes to the migration and invasion of cervical cancer cells.

Authors:  Danqing Wang; Qingli Li; Kemin Li; Ping Xiao; Rutie Yin
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

Review 2.  Radical Hysterectomy for Cervical Cancer: the Right Surgical Approach.

Authors:  Benny Brandt; Gabriel Levin; Mario M Leitao
Journal:  Curr Treat Options Oncol       Date:  2022-02-15

3.  Experiences of pretreatment laparoscopic surgical staging in patients with locally advanced cervical cancer: results of a prospective study.

Authors:  Myong Cheol Lim; Jaeman Bae; Jeong-Yoel Park; Soyi Lim; Sokbom Kang; Sang-Soo Seo; Joo-Yong Kim; Ju-Won Rho; Sang-Yoon Park
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

Review 4.  Advances in diagnosis and treatment of metastatic cervical cancer.

Authors:  Haoran Li; Xiaohua Wu; Xi Cheng
Journal:  J Gynecol Oncol       Date:  2016-07       Impact factor: 4.401

5.  Praeruptorin A Inhibits Human Cervical Cancer Cell Growth and Invasion by Suppressing MMP-2 Expression and ERK1/2 Signaling.

Authors:  Min-Hua Wu; Chia-Liang Lin; Hui-Ling Chiou; Shun-Fa Yang; Ching-Yi Lin; Chung-Jung Liu; Yi-Hsien Hsieh
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923

6.  Alpha-mangostin induces apoptosis through activation of reactive oxygen species and ASK1/p38 signaling pathway in cervical cancer cells.

Authors:  Chien-Hsing Lee; Tsung-Ho Ying; Hui-Ling Chiou; Shu-Ching Hsieh; Shiua-Hua Wen; Ruey-Hwang Chou; Yi-Hsien Hsieh
Journal:  Oncotarget       Date:  2017-07-18

7.  Incisional site metastasis in a patient with cervical carcinoma: a case report and review of the literature.

Authors:  C Iavazzo; K Madhuri; A Tailor; S Butler-Manuel
Journal:  Case Rep Obstet Gynecol       Date:  2012-11-26

8.  Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway.

Authors:  Ruey-Hwang Chou; Shu-Ching Hsieh; Yung-Luen Yu; Min-Hsien Huang; Yi-Chang Huang; Yi-Hsien Hsieh
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

9.  Sesamin inhibits cervical cancer cell proliferation by promoting p53/PTEN-mediated apoptosis.

Authors:  Tian-Ni Kuo; Chun-Shiang Lin; Guan-De Li; Cheng-Yi Kuo; Shao-Hsuan Kao
Journal:  Int J Med Sci       Date:  2020-08-25       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.